Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

CDH1 Germline Mutations in Lobular Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04206891
Recruitment Status : Recruiting
First Posted : December 20, 2019
Last Update Posted : December 20, 2019
Sponsor:
Information provided by (Responsible Party):
European Institute of Oncology

Brief Summary:

Invasive lobular breast carcinoma (ILBC) represents 5-15% of all invasive BCs. The CDH1 gene (OMIM no. 192090), located on the chromosome 16q22.1, encodes for the E-cadherin protein, a key regulator of cell adhesion. Loss of E-cadherin expression is frequently detected in LBC CDH1 germline loss-of-function mutations are associated with the autosomal dominant cancer-predisposition syndrome, hereditary diffuse gastric cancer (HDGC; OMIM no. 137215). The cumulative risk of LBC for women with a CDH1 mutation is estimated to be 42% (95% CI 23% to 68%) by 80 years, when it is a component of HDGC syndrome.

Recently, some authors described CDH1 germline mutations in women with in situ or ILBC with early onset (<45 or <50) and bilateral in situ or ILBC with no family history of HDGC. These results are opening a new scenario, suggesting that CDH1 could be a susceptibility gene for LBC in women without a family history of DGC.

The first aim of this study is to investigate prevalence of CDH1 in this specific population of women with early onset (<45 or <50) in situ or ILBC, bilateral LBC or LBC with no family history of HDGC.


Condition or disease
Lobular Breast Carcinoma CDH1 Gene Inactivation

Detailed Description:

Invasive lobular breast carcinoma (ILBC) represents 5-15% of all invasive BCs. LBC presents relevant differences in the transcriptomic profiles, metastatic pattern, and clinical behaviour compared to infiltrating ductal BC.

The CDH1 gene (OMIM no. 192090), located on the chromosome 16q22.1, encodes for the E-cadherin protein, a key regulator of cell adhesion. Loss of E-cadherin expression is frequently detected in LBC.

CDH1 germline loss-of-function mutations are associated with the autosomal dominant cancer-predisposition syndrome, hereditary diffuse gastric cancer (HDGC; OMIM no. 137215). The cumulative risk of LBC for women with a CDH1 mutation is estimated to be 42% (95% CI 23% to 68%) by 80 years, when it is a component of HDGC syndrome.

Recently, updated clinical guidelines for CDH1 testing criteria have been published. For LBC, CDH1 genetic screening has been suggested for families with diagnosed of both DGC and LBC (one diagnosis before the age of 50) and patients with bilateral or familial LBC before the age of 50.

Recently, some authors described CDH1 germline mutations in women with in situ or ILBC with early onset (<45 or <50) and bilateral in situ or ILBC with no family history of HDGC. These results are opening a new scenario, suggesting that CDH1 could be a susceptibility gene for LBC in women without a family history of DGC.

The investigators have revised all literature data about early-onset LBC and CDH1 germline mutations, excluding pedigrees associated with DGCs. In detail, 482 cases of LBCs were screened for CDH1 constitutional mutations. Family history for breast carcinoma was documented in 40.7 % of the considered probands and 20.3 % presented a bilateral BC manifestation. Mean age at onset was 46 years. Fourteen novels deleterious alterations (2.9 %) have been reported; 5 were missense (35.7 %), 3 mutations affected the splicing sites (21.4 %), 3 deletions (21.4 %), 2 insertions (14.3 %) and 1 stop codon (7.2 %). These mutations affect different CDH1 gene domains, spanning almost all 16 exons and introns 1-7-13 boundaries. Two missense mutations were defined as potentially pathogenic variants in vitro and in silico analysis [Corso et al. Fam Cancer 2016]. Overall, about 3% of the screened population with LBC have a mutation.

To date, no clear-cut genetic indicators for increased risk have been identified in patients with lobular breast cancer (LBC).

The first aim of this study is to investigate prevalence of CDH1 in this specific population of women with early onset (<45 or <50) in situ or ILBC, bilateral LBC or LBC with no family history of HDGC.

The investigators hypothesize that CDH1 is a susceptibility gene for LBC and that a novel and rare syndrome (called as hereditary LBC), independent from the classic HDGC setting, should be described, especially in subjects with early onset of LBC, before 45 years at diagnosis, and in bilateral LBC manifestation.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 487 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Understanding How CDH1 Germline Mutations Affect Hereditary Lobular Breast Cancer
Actual Study Start Date : December 1, 2018
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : December 31, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Group/Cohort
Group 1
Bilateral lobular invasive breast cancer
Group 2
Invasive lobular breast cancer with age at onset <= 45 years
Group 3
Invasive lobular breast cancer with family history for breast cancer
Group 4
In situ lobular breast cancer with age at onset <= 45 years
Group 5
In situ lobular breast cancer with family history for breast cancer



Primary Outcome Measures :
  1. Relative frequency of patients with a mutation in CDH1 germline [ Time Frame: 6 months ]
    Number of patients with mutation in CDH1 germline per each group identified


Secondary Outcome Measures :
  1. Frequency of patients with a mutation in CDH1 germline by disease status [ Time Frame: 6 months ]
    Number of patients with a mutation in CDH1 germline stratified by disease status to investigate the prevalence of this mutation status between invasive and in situ BC

  2. Frequency of patients with a mutation in CDH1 germline by clinical strata [ Time Frame: 6 months ]
    Number of patients with a mutation in CDH1 germline stratified by clinical data to investigate the prevalence of this mutation status betweenr early onset LBC (<45 years), bilateral LBC and LBC with family history for breast cancer



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

From 1997 to 2016 we collected data from a total of 1544 patients with invasive LBC and 230 with in situ histotype.

For CDH1 genetic screening, an additional population will be considered prospectively between the range 2017-2018 Among them we will have to identified patients with a BRCA1/2 pathogenetic mutation.

Criteria

Inclusion Criteria:

  • Bilateral lobular breast cancer or Lobular breast cancer with age at onset <= 45 years or Lobular breast cancer with family history for breast cancer
  • Patients with blood available in IEO biobank

Exclusion Criteria:

  • Patients with a previous cancer (except for colon cancer, stomach cancer and lobular breast cancer).
  • Patients with germline BRCA1/2 patogenetic mutation will be excluded

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04206891


Contacts
Layout table for location contacts
Contact: Giovanni Corso, MD 0039 02 94375161 giovanni.corso@ieo.it
Contact: Debora Macis debora.macis@ieo.it

Locations
Layout table for location information
Italy
European Institute of Oncology Recruiting
Milan, Italy
Contact: Giovanni Corso, MD         
Sponsors and Collaborators
European Institute of Oncology
Investigators
Layout table for investigator information
Principal Investigator: Giovanni Corso, MD European Institute of Oncology
Layout table for additonal information
Responsible Party: European Institute of Oncology
ClinicalTrials.gov Identifier: NCT04206891    
Other Study ID Numbers: IEO 0834/
First Posted: December 20, 2019    Key Record Dates
Last Update Posted: December 20, 2019
Last Verified: December 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Carcinoma, Lobular
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Ductal, Lobular, and Medullary